EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Revenue
EyePoint Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Revenue
$43.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$89.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$63.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$45B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
EyePoint Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
EyePoint Pharmaceuticals Inc
|
Total Revenue:
43.3m
USD
|
|
Country Us:
42m
USD
|
|
China:
1.1m
USD
|
|
United Kingdom:
100k
USD
|
Breakdown by Segments
EyePoint Pharmaceuticals Inc
|
Total Revenue:
43.3m
USD
|
|
Product Rights Agreement:
37.1m
USD
|
|
Yutiq:
3.1m
USD
|
|
Rpa:
1.1m
USD
|
EyePoint Pharmaceuticals Inc
Glance View
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
See Also
What is EyePoint Pharmaceuticals Inc's Revenue?
Revenue
43.3m
USD
Based on the financial report for Dec 31, 2024, EyePoint Pharmaceuticals Inc's Revenue amounts to 43.3m USD.
What is EyePoint Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
4%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for EyePoint Pharmaceuticals Inc have been 5% over the past three years , 16% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet